H.C. Wainwright Thinks Fibrocell Science Inc’s Stock is Going to Recover


H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fibrocell Science Inc (FCSC) today and set a price target of $22. The company’s shares opened today at $2.04, close to its 52-week low of $1.45.

According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -1.9% and a 34.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

Currently, the analyst consensus on Fibrocell Science Inc is a Moderate Buy with an average price target of $22.

See today’s analyst top recommended stocks >>

Based on Fibrocell Science Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.62 million. In comparison, last year the company had a GAAP net loss of $2.9 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts